CTOs on the Move

Charlotte Community Mental Health Services

www.sunline.net

 
Charlotte Community Mental Health Services is a Punta Gorda, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sunline.net
  • 1203 W Marion Ave
    Punta Gorda, FL USA 33950
  • Phone: 941.637.6116

Executives

Name Title Contact Details

Similar Companies

NeoLife International

NeoLife is a pioneer in whole food nutrition supplementation since 1958, with a commitment to end the trend of poor wellness and poverty.

GEMCare Health Plan

GEMCare Health Plan is a Bakersfield, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company`s current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012. EXPAREL and two other products have utilized the Pacira proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.

City of Melbourne FL

Terms Of Use Please be aware that when engaging with the City of Melbourne, Florida, through its social media pages, you are agreeing to the following terms of use: 1.) The Citys social media sites are not monitored at all times. Do NOT use thes...

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.